Galena Biopharma (GALE) slips 14% in the post-session after saying it intends to offer common stock and warrants for an unspecified amount. The company intends to use the net proceeds to conduct ongoing clinical trials for NeuVax and its Folate Binding Protein-E39. Piper Jaffray is acting as the sole book-running manager for the offering. [View news story]
I have been watching this stock for a while and the recent news and analysts write ups have been almost too good to be true. I believe this is a solid company with excelleent potential and I have been perplexed by the drop in the stocks value by about one third in the last 10 days or so. It is now evident that this common stock offering that will water down the value of the stock had been leaked and many individuals have been dumping the stock in anticipation of todays news. This stock will be offered a severe discount to its' recent price and it may be a very good opportunity to purchase it at the lower levels. Personally I think there should be two investigations, one to look at the people who dumped this stock over the last two weeks and the second to see if this stock was manipulated to make it run up to about $2.40 a share .
Neuralstem (CUR +7.2%) spikes, possibly related to a Crain's article reporting "amazing results" in a patient who received 500K stem cells derived by CUR. [View news story]
Here we go again. "Amazing results" mysteriously finding it's way into the press. True? I would say 99% not, but insiders will and speculaters will do very well unloading. If investers were buying into this strory then the move would be 70% and not 7%.
I sold of my Gern not long after they got out of the Stem Cell business. I mad a few dollars (but got hit when the stock price dived) but the reason for the purchase was buying into a leader in stem cell development. The company seemed to be going downhill and after holing on for some time it was time to hang it up. I am sorry that a company with what appeared to have cutting edge technology (which may yet be developed by Bio Time) has deteriorated to a point where it may cease to exist. I am considering Bio Time as an investment as I still believe that Geron's stem cell technology is very viable and has investment potential.
Pluristem Vs. Geron: An Insider's View Of The Stem Cell Story [View article]
Sorry that you misunderstood my original comment as I clearly stated in the opening statement the the information was "biased and should be considered a solication." My poorly worded followup was simply stating that the author was upfront regarding his position in the company and he was not acting as an impartial analyst.
Pluristem Vs. Geron: An Insider's View Of The Stem Cell Story [View article]
A clarification, when I said "no intent to decieve" this only refers to the position of the person who wrote the article, NOT THE SPEFICIC STATEMENTS CONCERNING THE VIABILITY OF THE COMPANY OR ITS' PRODUCT. The claims made in the article should be viewed critically
Pluristem Vs. Geron: An Insider's View Of The Stem Cell Story [View article]
It was obvious that this article is biased and should be considered a soliciation much like the numerous mailings supposedly issued by "legitimate" newsletters touting a stock which paid them to get people to buy the next hot stock. Seeking Alpha should create standards for allowing articles written by individuals who are "informing" readers concerning their own companies (although one can ask "how many SA articles are bought and paid for?") . A strong caveat should be clearly included for thos reading the article. That being said, I do not believe there was any intent to deceive and if a reader wants to do more research it is his responsibility to do diigence and understand the reality of investing in this type of venture.
Labopharm Just Became a Great Growth Stock [View article]
I have gotten very disenchanted with the reports in biomed reports as most of their so called information comes from the shills in the vatious drug companies. I do not trust their impartiality. I have yet to see a stock they have praised to the sky remain at even the original levels after getting a good pop from their pie in the sky reports. Now they are touting RNN and it is moving, maybe this will be the exception. Also when a stock they have written about plummets they completely ignore the issue, and never explain why prices are going down, down, down. DDSS is a stock that I have been wary of for many months. It has been manipulated and many people have been given "inside" information saying this stock will explode. I stayed away from it as my research did not indicate any real value, even when the promise of a time release anti depressent would be approved. If this drug had any real value a major or even minor copany would see it and cut a deal, this did not happen and they were forced to delute the stock value significantly with an offering. The guys manipulating this stock have made tremendous profits as they knew in advance what was going on. The little guys who were being used have lost big time. If the securites commission pulls the sales of this stock they could easily see who was miraculously selling at the top of the market to make big profits. If no company has offered to partner up by now you can be sure this product is dead. This company can not produce and sell this product alone and they do not have a viable prouct . The other "promising" product tramadol time release, is now history.
Galena Biopharma (GALE) slips 14% in the post-session after saying it intends to offer common stock and warrants for an unspecified amount. The company intends to use the net proceeds to conduct ongoing clinical trials for NeuVax and its Folate Binding Protein-E39. Piper Jaffray is acting as the sole book-running manager for the offering. [View news story]
Neuralstem (CUR +7.2%) spikes, possibly related to a Crain's article reporting "amazing results" in a patient who received 500K stem cells derived by CUR. [View news story]
Geron (GERN) has resumed trading after announcing it's discontinuing development of its GRN1005 brain cancer drug. Shares -12.2% AH to $1.30. [View news story]
Pluristem Vs. Geron: An Insider's View Of The Stem Cell Story [View article]
Pluristem Vs. Geron: An Insider's View Of The Stem Cell Story [View article]
Pluristem Vs. Geron: An Insider's View Of The Stem Cell Story [View article]
Labopharm Just Became a Great Growth Stock [View article]